title: Clinical outcome and angiographic results with novel polysulfone polymer coating paclitaxel eluting stent in real-world clinical practice: a clinical centre registry.
abstract: BACKGROUND
  The Intek-Apollo stent (Switzerland) employs a polysulfone polymer coating which has demonstrated low interaction with blood and high thrombo-resistance. The aim of this study was to assess the clinical and angiographic outcomes after Intek-Apollo stent utilisation in a real-world setting.
  
  
  METHODS
  A total of 130 patients (77.7% males) were enrolled with 174 lesions in native coronary arteries (92.4%), saphenous vein grafts (7.5%) and in-stent restenosis (6.3%). Indications for stenting were stable coronary artery disease (CAD) 52.3%, acute coronary syndrome (ACS) 37.7% and STEMI 10%. Clinical follow-up and coronary angiography (after symptoms occurrence or positive stress test) was performed at 6 and 12 months.The primary end points were target lesion revascularization (TLR) and target vessel revascularization (TVR), while secondary end points were major adverse cardiac events (MACE) during the follow-up period.
  
  
  RESULTS
  The mean age of patients included was 61.62±11.13 years. Complex lesions treatment (ostial, bifurcation) reached 13.7%. Mean stenosis diameter was 83.52±10.5%. Reference vessel diameter was 2.85±0.39 mm with a mean lesion length of 14.66±4.5mm. Average stent size was 2.93±0.39mm × 16.6±4.73 mm. At 15±3 months, primary events included TLR (4.6%), TVR (4.6%) and MACE (2.3%). There was 1one myocardial infarction and no cardiac death). No incidence of early or late stent thrombosis was demonstrated.
  
  
  CONCLUSIONS
  Intek-Apollo stent implantation is safe and efficient in a real world population. The unique properties of polysulfone polymer coating can effectively protect from late stent thrombosis and lead to reduced rates of TLR, TVR and MACE.
authors.affiliation: 2nd Department of Cardiology, Evaggelismos General Hospital, Athens, Greece. makisgab@yahoo.gr
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Gavrielatos
authors.forename: Prodromos L
authors.initials: PL
authors.lastname: Anthopoulos
authors.forename: Loukas K
authors.initials: LK
authors.lastname: Pappas
authors.forename: Isidoros
authors.initials: I
authors.lastname: Gavaliatsis
authors.forename: Anastasios
authors.initials: A
authors.lastname: Salachas
authors.forename: Georgios
authors.initials: G
authors.lastname: Ifantis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Antonelis
mesh_terms: D000368:Aged; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D017023:Coronary Angiography / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy; D003327:Coronary Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D003331:Coronary Vessels / Q000473:pathology; D054855:Drug-Eluting Stents; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging / Q000453:epidemiology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use; D011108:Polymers / Q000627:therapeutic use; D012042:Registries; D013450:Sulfones / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D011108:Polymers; D013450:Sulfones; C017662:polysulfone P 1700; D017239:Paclitaxel